Sanjay Kshirsagar

Sanjay Kshirsagar


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2011 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
SKSanjay Kshirsagar
Sanjay Kshirsagar
MBMangesh R. Bhalekar
Mangesh R. Bhalekar
JPJiten N. Patel
Jiten N. Patel
SMSantosh K. Mohapatra
Santosh K. Mohapatra
NSNitin S. Shewale
Nitin S. Shewale
Context: Nanoparticles for colon-specific drug delivery system are known for their specific accumulation in the inflamed tissue in the colon and may therefore allow a selective delivery to the site of inflammation for the treatment of inflammatory bowel disease (IBD). Objective: The objective of this study was to formulate and evaluate nanocapsules (NC), an oral system designed to achieve site-specific and instant drug release in colon for effective treatment of IBD. Materials and methods: Prednisolone (PD), a typical glucocorticoid, has been widely used for the treatment of IBD. In this study, nanoprecipitation method was used to prepare polymeric NC of PD with pH responsive polymer Eudragit S100. The effect of several formulation variables such as surfactant, oil, and polymer on the PD-NC properties (average size, drug release rate, and drug entrapment) was investigated. In vitro drug release study was done by changing pH method and an in vivo study on rat was done to ascertain efficiency of PD-NC to release drug specifically in colon. Results and discussion: The optimized formulations lead to the preparation of PD-NC with a mean size of 567.87 nm, high encapsulation efficiency of 90.21%. In vitro studies reveal that NC releases the drug after 4.5-h lag time corresponding to time to reach colonic region, and in vivo studies show that NC release drug after 3-h lag time in rat corresponds to arrival in colon. Conclusion: The above NC formulation of PD is the targeted drug to the colon and may provide effective way of treatment of colonic disease.

21 May 2010 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
PDF file
SKSanjay Kshirsagar
Sanjay Kshirsagar
MBMangesh R. Bhalekar
Mangesh R. Bhalekar
RURajesh R. Umap
Rajesh R. Umap
Objective: Targeted delivery systems for the treatment of Inflammatory bowel disease (IBD) are designed to increase local tissue concentrations of anti-inflammatory drugs from lower doses compared with systemic administration. The objective of this study was to formulate and evaluate an oral system designed to achieve site-specific and instant drug release in the colon for effective treatment of IBD. Materials and methods: The system consists of a core tablet containing the model drug diclofenac sodium, superdisintegrant sodium starch glycolate, and coated with enteric polymer Eudragit FS 30 D to achieve different total percentage weight gain. Drug release studies were carried out using a changing pH method. A placebo formulation containing barium sulphate in the tablet was administered to human volunteers for in vivo X-ray studies. SEM studies were performed to determine coating thickness and film topography. Results: In vitro studies revealed that the tablet with 10% coating level released the drug after 5 h lag time corresponding to the colonic region. Tablets with 10% coating level could maintain their integrity in human volunteers for 5 h, approximating colon arrival time and release the drug instantaneously. Discussion: Colon-targeting and instant drug release for 10% coating level was due to the dissolution of the Eudragit FS 30 D and the immediate release effect of superdisintegrant. It was observed that as the coating level increased, the lag time also increased. This was because of increased diffusion path length and tortuosity at higher coating levels. Conclusion: An in vivo-in vitro study revealed that not only the sensitivity of the polymer to the pH environment but also the thickness of coating plays an important role in colon delivery and the tablet with 5% superdisintegrant and 10% coating level achieved the desired performance of the colon targeting.

31 March 2011 in Drug Delivery
Verified
Journal Article
Closed access
SKSanjay Kshirsagar
Sanjay Kshirsagar
MBM. R. Bhalekar
M. R. Bhalekar
NSN. S. Shewale
N. S. Shewale
VGV. P. Godbole
V. P. Godbole
PJP. K. Jagdale
P. K. Jagdale
SMS. K. Mohapatra
S. K. Mohapatra
The aim of the present study is to develop colon-targeted drug delivery systems for diclofenac sodium which release the drug specifically and instantly at target site using amylose as a carrier. Coating formulations were designed based on the full factorial design. The evaluated responses were lag time prior to drug release and T90. Compression-coated tablets of diclofenac sodium containing various proportions of amylose and HPMC were prepared. In vitro drug release studies were done by changing pH method with enzyme. In vivo studies were done to confirm the potential of formulation to release the drug at target site. The dissolution data revealed that the ratio of polymers is very important to achieve optimum formulation. Results showed that the tablet prepared according to the above formulation released drug instantly at pH 6.8 (simulating colonic pH). An in vivo study shows that optimized formulation disintegrated in the target region. The results of this study revealed that factorial design is a suitable tool for optimization of coating formulations to achieve colon delivery. It was shown that coating formulation consisting of amylose 285 mg and HPMC 150 mg coating has the potential for colonic delivery of diclofenac sodium irrespective of change in pH in a patient with IBD.

19 May 2009 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SKSanjay Kshirsagar
Sanjay Kshirsagar
MBM.R. Bhalekar
M.R. Bhalekar
RPR.P. Pawar
R.P. Pawar
Crohn's disease is a type of inflammatory bowel disease that frequently affects the ileo-cecal region of the gastrointestinal tract. For effective treatment of this disease, a site-targeting drug in the ileo-cecal region is essential. Budesonide (BD) is a synthetic, non-halogenated glucocorticoid and is the drug of choice for the treatment of Crohn's disease. The present study is an attempt to develop the dosage form of a BD tablet to achieve targeted drug release in the ileo-cecal region. The BD tablets are coated with Eudragit FS 30 D, which is a polymer that specifically dissolves at and above pH 6.8. The in vitro drug release and in vivo tablet disintegration (using X-ray radiography) were carried out. The coating process was optimized successfully. The in vitro performance of the tablet with coating thickness showed that the tablet did not disintegrate till 4.5 hours, which represents the transit time to the ileo-cecal region. In vivo studies also established that the tablet lasted till 4.5 hours. The tablet containing 0.5% superdisintegrant and 10% coating thickness was able to deliver BD effectively to the ileo-cecal region, thus making it a promising drug delivery system for the treatment of Crohn's disease.

16 November 2018 in Pharmaceutical Journal of Sri Lanka
Verified
Journal Article
Open access
PDF file
NTNilima Thombre
Nilima Thombre
KPK. N. Pawar
K. N. Pawar
YPY. A. Patil
Y. A. Patil
SKSanjay Kshirsagar
Sanjay Kshirsagar